Dental Pain Clinical Trial
Official title:
A Double-Blind, Double-Dummy, Placebo- and Active Controlled Evaluation of the Efficacy, Safety and Tolerability of Buprenorphine HCl Buccal Film in the Treatment of Pain Associated With Third Molar Extraction
Verified date | January 2016 |
Source | Endo Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to assess the activity of buprenorphine hydrochloride (HCl) buccal film in the treatment of dental pain.
Status | Completed |
Enrollment | 153 |
Est. completion date | November 2009 |
Est. primary completion date | November 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - extraction of 2 or more third molars, at least 1 of which must be fully or partially impacted in mandibular bone - males or non-pregnant females, aged 18 to 45 years - good general health and capable of providing informed consent Exclusion Criteria: - history of substance abuse or dependence - positive urine toxicology screen or alcohol breath test - history of hypersensitivity to or allergy to any study drug - donation of blood within prior 30 days - use of analgesics, caffeine, sedatives, antidepressants, anticoagulant or antiplatelet agents within 24 hours |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Premier Research Group Limited | Austin | Texas |
United States | Premier Research Group Limited | Salt Lake City | Utah |
United States | Donald P. Bandy, DDS | San Marcos | Texas |
Lead Sponsor | Collaborator |
---|---|
Endo Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sum of Pain Intensity Difference From Baseline to 8 Hours | Time-weighted sum of pain intensity difference from baseline to 8 hours (SPID-8) where total score ranges from -80 (worst) to 80 (best) and a higher value indicates greater pain relief. Pain intensity was recorded using an 11-point numeric rating scale (NRS), where 0=none and 10=worst pain imaginable, in response to "What is your pain level at this time?" | Baseline, 8 hours | No |
Secondary | Total Pain Relief Over 8 Hours | Time-weighted sum of total pain relief over 8 hours (TOPAR-8) where total score ranges from 0 (worst) to 32 (best) and higher values indicate greater pain relief. Pain relief (PAR) was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to "How much relief have you had from your starting pain?" | 8 hours | No |
Secondary | Sum of Pain Relief and Intensity Differences Over 8 Hours | Time-weighted sum of PAR and pain intensity difference (PID) over 8 hours (SPRID-8) where total score ranges from -80 (worst) to 112 (best) and higher values indicate greater pain relief. PAR was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to "How much relief have you had from your starting pain?" PID determined as the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to "What is your pain level at this time?" | 8 hours | No |
Secondary | Sum of Pain Relief and Intensity Differences Over 2 Hours | Time-weighted sum of PAR and PID over 2 hours (SPRID-2) where total score ranges from 0 (worst) to 8 (best) and higher values indicate greater pain relief. PAR was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to "How much relief have you had from your starting pain?" PID determined as the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to "What is your pain level at this time?" | 2 hours | No |
Secondary | Peak Pain Intensity Difference | The maximum PID at any time following dosing determined from the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to "What is your pain level at this time?" | 24 hours | No |
Secondary | Peak Pain Relief | Maximum pain relief (PAR) at any time following dosing, recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to "How much relief have you had from your starting pain?" | 24 hours | No |
Secondary | Onset of Analgesia | Time to onset of analgesia defined as median time to perceptible pain relief if confirmed by experiencing meaningful pain relief from time of study drug administration. | 8 hours | No |
Secondary | Duration of Analgesia | Duration of analgesia was the median time to use of rescue medication; earliest concomitant medication start time for medications identified as rescue medications from time of study drug administration. | 24 hours | No |
Secondary | Percentage of Participants Reporting a Global Rating of Study Drug as "Excellent" | Subjects rated the global effectiveness of study drug as poor, fair, good, or excellent, in response to "Overall, how would you rate the study medication you received for pain?" | 8 hours and 24 hours | No |
Secondary | Percentage of Participants With "Excellent" Investigator Global Rating of Study Drug | Investigators rated the global effectiveness of study drug as poor, fair, good, or excellent, in response to "Overall, how would you rate the study medication for this subject?" | 24 hours | No |
Secondary | Change From Baseline in Cognitive Assessment Using CNS-VS | Cognition assessed using computer-based CNS Vital Signs® neurocognitive function test (CNS-VS), including symbol digit coding, Stroop test, and shifting attention test to measure cognitive flexibility, executive functioning, processing speed, and reaction time(*). Scores are computed from raw score calculations using the data values of individual subtests. An asterisk denotes that "lower score is better", otherwise higher scores are better. | Baseline (screening), 2 hours 15 minutes postdose | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00942448 -
Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery
|
Phase 3 | |
Completed |
NCT00954356 -
Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction
|
Phase 2 | |
Completed |
NCT00985439 -
Study of Diclofenac Capsules to Treat Dental Pain
|
Phase 2 | |
Completed |
NCT00943098 -
Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery
|
Phase 3 | |
Completed |
NCT02966067 -
A Split Mouth Trial to Compare Microneedles vs. Standard Needles in Dental Anaesthetic Delivery
|
N/A | |
Completed |
NCT01960114 -
Study of Long-Acting Acetaminophen in Postoperative Dental Pain
|
Phase 2 | |
Completed |
NCT01229228 -
Study of Naproxen Capsules to Treat Dental Pain
|
Phase 2 | |
Completed |
NCT01177423 -
Efficiency Evaluation of Intradiploic Intra-osseus Anesthesia Versus Inferior Alveolar Nerve Block
|
N/A | |
Completed |
NCT03328208 -
Nonpharmacologic Reduction of Periprocedural Distress and Drug Use
|
N/A | |
Completed |
NCT05236101 -
Validation of Child Drawing Hospital Scale (CD: H) and the Place of the Drawing in the Evaluation of Dental Anxiety
|
N/A | |
Completed |
NCT00542035 -
A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction
|
Phase 2 | |
Completed |
NCT04231955 -
Comparison of Different Pain Rating Scales in Patients With Symptomatic Teeth
|
N/A | |
Completed |
NCT02096926 -
Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery
|
Phase 4 | |
Completed |
NCT05369936 -
Pain Perception: on Relationships Between Dental Anxiety and Olfaction
|
N/A | |
Recruiting |
NCT05351099 -
Dental Block for Pain Relief in ED Dental Pain Patients
|
||
Not yet recruiting |
NCT06269406 -
A Combination of Ibuprofen With Curcumin Covered With Liquorice Root Supplementation in the Management of Postoperative Dental Pain in Adults
|
N/A | |
Recruiting |
NCT05443009 -
Self-Reported Pain in Children Submitted to Single Infiltration of Articaine During Primary Molar Extraction
|
Phase 4 | |
Terminated |
NCT02161354 -
Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars
|
Phase 2 | |
Completed |
NCT04949126 -
Self Medication in Odontology (AUDE)
|
||
Completed |
NCT03652818 -
Dental Pain Study of Analgesics in Patients Undergoing Molar Removal
|
Phase 2 |